ArticleFrontiers in immunology2025
Multi-omics insights into the role of mitophagy receptor-related genes in glioma prognosis and immune microenvironment remodeling.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genome-wide and co-expression network dissection ofFrontiers in plant science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitophagy receptor-related genes (MRRGs) orchestrate mitochondrial quality control and may shape glioma progression and immune tolerance, yet their integrated prognostic and immunobiological significance remains unclear. Methods: We combined WGCNA, single-cell AUCell scoring, and LASSO/Cox modeling across public glioma cohorts to derive and externally validate a 17-gene MRRG risk signature. Multi-omics comparisons (transcriptome, pathway enrichment, mutation, and GWAS association), immune infiltration, and therapy response prediction were performed. Core driver(s) were interrogated by Results: The MRRG signature robustly stratified overall survival across independent datasets and remained an independent prognostic factor after multivariable adjustment. High-risk tumors exhibited activation of P53 signaling and MAPK signaling pathway, coupled with immunosuppressive remodeling characterized by increased M2-like macrophage infiltration and T cell dysfunction. Integrative analyses highlighted IFNAR2 as a central node; its silencing impaired glioma cell proliferation, invasion, and metastatic potential, while Conclusion: We present and validate a 17-MRRG prognostic model that links mitophagy receptors to glioma immunosuppression and clinical outcome, and identify IFNAR2 as a functional driver. These findings provide a rationale for incorporating MRRG profiling into prognostic assessment and therapeutic decision-making in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.